Where can I find more detailed information about the Aetna acquisition?

More detailed information about the Aetna acquisition can be found in the definitive joint proxy statement/prospectus filed by CVS Health with the SEC on Form S-4, which was declared effective on February 9, 2018. Investors are urged to read this document and other related filings carefully.

Does this filing contain Aetna's financial statements?

This specific 8-K filing does not contain Aetna's financial statements directly. However, it references exhibits (Exhibit 99.1 and 99.2) that contain information related to Aetna's business, operations, risks, and regulatory matters. For detailed financial statements, investors should refer to Aetna's and CVS Health's respective SEC filings, including their Annual Reports on Form 10-K.

What are the 'Participants in the Solicitation' mentioned in the filing?

The 'Participants in the Solicitation' section identifies individuals from CVS Health and Aetna, including their directors and executive officers, who may be considered participants in the solicitation of proxies for the proposed transaction. Information about these individuals and their interests can be found in their respective company filings and the definitive joint proxy statement/prospectus.

CVS 8-K SEC Disclosure

Q: What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to provide additional selected information to investors about Aetna Inc.'s business, operations, material risks, and regulatory matters in the context of CVS Health's pending acquisition of Aetna. It also includes necessary consents from Aetna's auditors.

Summary

This 8-K filing from CVS Health dated March 6, 2018, primarily serves to provide additional information to investors regarding the pending acquisition of Aetna Inc. It emphasizes that the document is for informational purposes and not an offer to sell or solicit any votes or approvals related to the transaction. The filing directs investors to a previously filed registration statement (Form S-4) which includes a joint proxy statement and prospectus, declared effective by the SEC, and urges them to review these documents for comprehensive details about the proposed transaction. The report also includes consents from Aetna's independent registered public accounting firm, KPMG LLP, for their inclusion in CVS Health's registration statement. Crucially, it highlights that CVS Health is providing selected information on Aetna's business, operations, material risks, and regulatory matters as exhibits to this filing, further informing stakeholders about the target company as the transaction progresses. The filing also reiterates forward-looking statements and associated risks, advising investors to consult SEC filings for a complete understanding of these factors.

Key Highlights

1CVS Health is providing supplemental information regarding Aetna's business, operations, material risks, and regulatory matters in connection with the pending acquisition.
2The filing directs investors to the definitive joint proxy statement/prospectus (Form S-4) for comprehensive details on the proposed Aetna transaction.
3The registration statement containing the joint proxy statement/prospectus has been declared effective by the SEC, and materials have been mailed to stockholders.
4Consents from Aetna's independent auditor, KPMG LLP, are included, enabling their reference in CVS Health's registration statement.
5The filing explicitly states it is for informational purposes and not an offer or solicitation for securities or votes.
6Investors are strongly encouraged to read the joint proxy statement/prospectus and other SEC filings for complete information.
7Forward-looking statements about the transaction and its potential impacts are reiterated, with emphasis on associated risks and uncertainties.

CVS HEALTH Corp 8-K Report, Corporate Update (Mar 6, 2018)

Summary

Key Highlights

Frequently Asked Questions